Zobrazeno 1 - 10
of 254
pro vyhledávání: '"Christelle Levy"'
Autor:
Garazi Ruiz de Azua, Isabelle Kousignian, Ines Vaz‐Luis, Antonio Di Meglio, Elsa Caumette, Julie Havas, Elise Martin, Anne‐Laure Martin, Ophelie Querel, Laurence Vanlemmens, Barbara Pistilli, Charles Coutant, Paul Henri Cottu, Asma Dhaini Merimeche, Florence Lerebours, Olivier Tredan, Christelle Jouannaud, Christelle Levy, Agnes Dumas, Gwenn Menvielle
Publikováno v:
Cancer Medicine, Vol 12, Iss 18, Pp 19091-19101 (2023)
Abstract Purpose This study assessed sustainable return to work (SRTW) of breast cancer survivors (BCS). Methods We used data from the prospective French cohort, CANTO. We included 1811 stage I–III BCS who were 50 (OR = 0.59; 95%CI = 0.43–0.82),
Externí odkaz:
https://doaj.org/article/caaf22a6096241ad9f5aa1968c778c76
Autor:
François Gernier, Jean-Michel Grellard, Charlotte Dupont, Hervé Castel, Marie Fernette, François Lahaye, Rose-Marie Charles, Tiphaine Leroux, Céline Ory, Audrey Faveyrial, Adeline Morel, George Emile, Christelle Levy, Carine Segura, Djelila Allouache, Alison Johnson, Julien Geffrelot, Katharina Gunzer, Anaïs Lelaidier, Gilles Girault, Coraline Dubot-poitelon, Chankannira San, Justine Lequesne, Bénédicte Clarisse
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-10 (2023)
Abstract Background Non-metastatic breast cancer treatment is mainly based on surgery, with or without chemotherapy, radiotherapy and/or hormone therapy. To reduce the risk of hormone receptor positive (HR+) disease recurrence, hormone therapy is pre
Externí odkaz:
https://doaj.org/article/26a7a9b19d2643669b2a86b963b0dcee
Autor:
Coralie Courtinard, Sophie Gourgou, William Jacot, Matthieu Carton, Olivier Guérin, Laure Vacher, Aurélie Bertaut, Marie-Cécile Le Deley, David Pérol, Patricia Marino, Christelle Levy, Lionel Uwer, Geneviève Perrocheau, Renaud Schiappa, Florence Bachelot, Damien Parent, Mathias Breton, Thierry Petit, Thomas Filleron, Agnès Loeb, Simone Mathoulin-Pélissier, Mathieu Robain, Suzette Delaloge, Carine Bellera
Publikováno v:
BMC Medicine, Vol 21, Iss 1, Pp 1-13 (2023)
Abstract Background Overall survival (OS) is the gold standard endpoint to assess treatment efficacy in cancer clinical trials. In metastatic breast cancer (mBC), progression-free survival (PFS) is commonly used as an intermediate endpoint. Evidence
Externí odkaz:
https://doaj.org/article/95e587a2739d4813945eb54f7074bcab
Autor:
François Cherifi, Angélique Da Silva, Alison Johnson, Cécile Blanc-Fournier, Olivia Abramovici, Antonin Broyelle, Christelle Levy, Djelila Allouache, Ioana Hrab, Carine Segura, Adeline Morel, Maud Villemin, Clémence Boscher, Coraline Dubot-Poitelon, Pauline Rottier, Justine Lequesne, George Emile
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Background HER2 expression has a prognostic and predictive impact in early-stage breast cancer (BC). HER2 positive BC (immunohistochemistry (IHC) score 3 + or 2 + with in situ hybridization (ISH) amplification) are treated with HER2 targeted
Externí odkaz:
https://doaj.org/article/729e7bcb52cf4560a57a3e58bf74b4ff
Autor:
Antoine Vasseur, Matthieu Carton, Severine Guiu, Paule Augereau, Lionel Uwer, Marie-Ange Mouret-Reynier, Christelle Levy, Jean-Christophe Eymard, Jean-Marc Ferrero, Marianne Leheurteur, Anthony Goncalves, Marie Robert, Thibault De La Motte Rouge, Thomas Bachelot, Thierry Petit, Marc Debled, Thomas Grinda, Isabelle Desmoulins, Laurence Vanlemmens, Vincent Nicolaï, Gaëtane Simon, Luc Cabel
Publikováno v:
Breast, Vol 65, Iss , Pp 136-144 (2022)
Background: Taxanes are one of the most effective chemotherapies (CT) in breast cancer (BC), but the efficacy of taxanes rechallenge in early metastatic relapse has been poorly studied in patients previously treated by taxanes in the (neo)adjuvant se
Externí odkaz:
https://doaj.org/article/3e5e3d1b6d254f9091fd5376422aa2e4
Autor:
Renaud Sabatier, Cécile Vicier, Séverine Garnier, Arnaud Guille, Nadine Carbuccia, Nicolas Isambert, Florence Dalenc, Marie Robert, Christelle Levy, Jihane Pakradouni, José Adelaïde, Max Chaffanet, Patrick Sfumato, Emilie Mamessier, François Bertucci, Anthony Goncalves
Publikováno v:
Molecular Oncology, Vol 16, Iss 10, Pp 2057-2070 (2022)
The phosphatidylinositol‐3‐kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway is frequently activated in HER2‐negative breast cancer and may play a role in taxane resistance. The phase IB/II TAKTIC trial (NCT01980277) has shown that
Externí odkaz:
https://doaj.org/article/703ca5faef324c5b808393f820024f09
Autor:
Pauline Rottier, George Emile, Alison Johnson, Christelle Levy, Djelila Allouache, Ioana Hrab, Carine Segura, Adeline Morel, Maud Villemin, Coraline Dubot-Poitelon, Louis Boismoreau, François Cherifi, Justine Lequesne, Angélique Da Silva
Publikováno v:
Frontiers in Oncology, Vol 12 (2023)
BackgroundCyclin dependent kinase inhibitors (CdK4/6i) changed the course of hormone receptor positive (HR+) HER2 negative (HER2-) metastatic breast cancer (mBC). To date, no factors have been shown to predict response to CdK4/6i. Neutrophil-to-lymph
Externí odkaz:
https://doaj.org/article/d562fdba4d99430585cc0e12cca5da20
Autor:
Amanda Bortolini Silveira, François-Clément Bidard, Marie-Laure Tanguy, Elodie Girard, Olivier Trédan, Coraline Dubot, William Jacot, Anthony Goncalves, Marc Debled, Christelle Levy, Jean-Marc Ferrero, Christelle Jouannaud, Maria Rios, Marie-Ange Mouret-Reynier, Florence Dalenc, Caroline Hego, Aurore Rampanou, Benoit Albaud, Sylvain Baulande, Frédérique Berger, Jérôme Lemonnier, Shufang Renault, Isabelle Desmoulins, Charlotte Proudhon, Jean-Yves Pierga
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-9 (2021)
Abstract Circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) are two cancer-derived blood biomarkers that inform on patient prognosis and treatment efficacy in breast cancer. We prospectively evaluated the clinical validity of quantifyin
Externí odkaz:
https://doaj.org/article/defc150529374d2a9813a467847b33d8
Autor:
Pietro Lapidari, Arnauld Gbenou, Julie Havas, Elise Martin, Barbara Pistilli, Anne-Laure Martin, Sibille Everhard, Charles Coutant, Paul Cottu, Anne Lesur, Florence Lerebours, Olivier Tredan, Laurence Vanlemmens, Christelle Jouannaud, Christelle Levy, Olivier Rigal, Marion Fournier, Fabrice Andre, Ines Vaz-Luis, Antonio Di Meglio
Publikováno v:
Breast, Vol 57, Iss , Pp 43-48 (2021)
We assessed long-term associations of Granulocyte-Colony Stimulating Factors (G-CSF) use with patient-reported outcomes (PROs) and hematologic toxicity among chemotherapy-treated, early-stage breast cancer patients in CANTO (NCT01993498).Among 2920 p
Externí odkaz:
https://doaj.org/article/ef4f2574efb14de2b2de94ef9c41d09a
Autor:
Luc Cabel, Matthieu Carton, Barbara Pistilli, Florence Dalenc, Laurence Vanlemnens, Christelle Levy, William Jacot, Michel Debled, Agnes Loeb, Audrey Hennequin, Thibault De la Motte Rouge, Lilian Laborde, Carine Laurent, E. Chamorey, Damien Parent, Thierry Petit, Marie-Ange Mouret-Reynier, Mario Campone, Geneviève Perrocheau, Claire Labreveux, Thomas Bachelot, Mathieu Robain, Florence Lerebours
Publikováno v:
Breast, Vol 56, Iss , Pp 18-25 (2021)
Purpose: Among metastatic breast cancer (MBC) patients, those with a triple-negative breast cancer phenotype (mTNBC) have the worst prognosis, but the benefit of chemotherapy beyond second line on outcome remains uncertain. The purpose of this study
Externí odkaz:
https://doaj.org/article/9d7301cf07844d3c90e440221410f725